We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Periodontal Rapid Diagnostic Test Could Calculate Risk for Heart and Lung Disease

By LabMedica International staff writers
Posted on 21 Oct 2022

Gum (periodontal) disease is caused by infection in the gums and is the leading cause of tooth loss. More...

It gets more common with age, and 50% of 60-year olds will have periodontal disease in at least a mild form. However, untreated gum disease also has wide-ranging and serious effects on the rest of the body, where it correlates with an inflammatory response that affects the course of disease in other conditions. In type 2 diabetes, it increases the risk of heart failure, in cardiovascular disease it increases the risk of stroke or heart failure, in rheumatoid arthritis it increases the severity of disease, while in emphysema (also known as chronic obstructive pulmonary disease or COPD), it increases the risk of irreversible step-changes in disease severity. For people with these conditions, early detection and treatment of gum disease is a priority. Gum disease is usually identified in the dentist’s chair, when dental hygienists or dentists look for indicators such as tooth movement, sensitivity, gum bleeding or swelling. Now, researchers developing a rapid test for gum disease expect the technology - a probe for use in point of care settings such as dental surgeries or pharmacies - to play a pivotal role in early detection of heart or lung disease, type 2 diabetes and rheumatoid arthritis.

Researchers from the University of Birmingham (Edgbaston, UK) have devised a new technique that could provide a rapid and accurate assessment of both the presence and extent of gum disease from a sample of saliva that can be taken in any healthcare setting. Their method consists of a specialized probe and a detector that provides a quantitative measurement of biomarkers that indicate both the presence of gum disease and its severity. The biomarker panel was identified and validated by a team of researchers. The researchers have also received funding to develop a prototype of the new device, which is expected to be available within a year. In the long-term, the researchers expect to develop a probe that is small enough to be inserted into the space between gums and teeth, allowing dentists to collect fluid from specific areas in the mouth, and accurately identify the site of infection.

“We believe the device we are prototyping will be the first dental probe that can identify periodontal disease in this way,” said Professor Tim Albrecht, School of Chemistry, University of Birmingham. “It will detect periodontitis quickly and easily in a variety of healthcare settings, opening up opportunities for monitoring and early intervention in the patients with comorbid disease, who would benefit most from rapid treatment for periodontitis.”

“The ability to detect and profile disease biomarkers in real time will allow monitoring for disease severity, and in particular the transition between milder and more severe forms of gum disease,” added Dr. Melissa Grant, School of Dentistry, University of Birmingam. “This will benefit not only dental health, but also reduce costs and capture patients for whom periodontal treatment may, in the long run, be life-saving.”

Related Links:
University of Birmingham 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.